Chronic Pain as a Disease of Aging: The Role of Cellular Senescence and Inflammatory Signaling

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Chronic Pain as a Disease of Aging

Chronic pain represents the most widespread health condition globally, imposing a significant socioeconomic burden and markedly impairing quality of life. Despite its prevalence, chronic pain has historically received relatively limited research attention, largely because it is not a direct cause of mortality. However, large-scale epidemiological studies now demonstrate that chronic pain can negatively influence lifespan. Data from the UK Biobank, which included more than 14,000 recorded deaths prior to 2018, revealed that chronic widespread pain is linked with a 59% increase in all-cause mortality, even after adjusting for lifestyle factors.

The biological mechanisms underpinning this association are increasingly tied to telomere biology. Telomeres, repetitive DNA–protein complexes capping eukaryotic chromosomes, are markers of cellular aging and survival. Shortening or dysfunction of telomeres has been associated with numerous age-related conditions. Stress and inflammation, both prominent features of chronic pain, are known to accelerate telomere attrition. Indeed, reduced leukocyte telomere length has been documented in patients with migraine, fibromyalgia, osteoarthritis, and endometriosis.

A sex-stratified analysis of UK Biobank participants showed that in men, each additional chronic pain site corresponded with a reduction in life expectancy of approximately 0.2 years. Interestingly, this relationship was not observed in women, highlighting possible sex-specific differences in pain biology and aging trajectories.

Cellular Senescence, Telomere Dysfunction, and Pain Mechanisms

Cellular senescence is a state of permanent cell-cycle arrest triggered by various stressors, most commonly telomere dysfunction. This arrest is mediated through the p53/p21 and p16INK4a pathways, which ultimately converge on retinoblastoma protein. Senescent cells are metabolically active and secrete a pro-inflammatory milieu known as the senescence-associated secretory phenotype (SASP). This secretome contains cytokines, chemokines, growth factors, and proteases that disrupt tissue homeostasis and perpetuate chronic inflammation.

Senescence and telomere dysfunction have been implicated in a wide array of conditions, including atherosclerosis, dementia, Alzheimer’s disease, cardiovascular disorders, and osteoarthritis. Although senescence has been linked with diseases that involve pain, such as osteoarthritis and spinal degeneration, a direct mechanistic connection to chronic pain itself had not been fully defined until recently.

Evidence from Animal Models: Telomere Dysfunction and Persistent Pain

Studies in rodent models demonstrate that peripheral nerve injury leads to telomere shortening and senescent cell accumulation in the spinal cord long after the initial insult. These changes occur in an injury-, sex-, and side-specific manner, with microglial cells in the male spinal cord particularly affected.

Experimental evidence shows that genetically determined telomere shortening can drive pain hypersensitivity via p53-dependent senescence. Male rodents with chronic nerve injury not only displayed increased cellular senescence but also had reduced survival, linking telomere biology directly with pain and lifespan. This aligns with human biobank data suggesting a stronger connection between pain, telomere dynamics, and mortality in men.

Senescence-Driven Inflammation and Allodynia

Senescent cells accumulate in the dorsal horn of the spinal cord following nerve injury, secreting SASP mediators that contribute to sustained inflammation. These inflammatory factors, including interleukins and growth modulators, are well known to sensitize nociceptive pathways, thereby promoting mechanical allodynia.

Histological staining for senescence-associated β-galactosidase revealed significant increases in senescent cells in injured male spinal cords compared to controls. Moreover, the degree of cellular senescence strongly correlated with behavioral measures of pain hypersensitivity, reinforcing the concept that senescent cell accumulation contributes directly to persistent neuropathic pain.

Targeting Senescent Cells as a Therapeutic Strategy

Given the role of p53 in mediating senescence and apoptosis, therapeutic strategies have focused on eliminating senescent cells to alleviate pain. One such approach involved the use of a FOXO4-derived D-retro inverso (FOXO4-DRI) peptide, which disrupts the interaction between p53 and FOXO4, leading to selective apoptosis of senescent cells.

In male mice subjected to sciatic nerve injury, intrathecal administration of FOXO4-DRI for five consecutive days resulted in a reversal of mechanical allodynia that persisted beyond the treatment period. The effect was reproducible with reinjection but absent in young mice or female cohorts. Molecular analysis confirmed a reduction in expression of p53 pathway genes and SASP mediators such as interleukin-1β and interleukin-6 in treated male mice.

These findings provide causal evidence that senescent, p53-positive cells in the spinal cord maintain long-term hypersensitivity following nerve injury. Selective elimination of these cells reduces inflammatory signaling and alleviates pain, underscoring the potential of senolytic therapies in chronic pain management.

Clinical Implications

The convergence of human epidemiological data and animal model research suggests that telomere biology and cellular senescence play a central role in chronic pain pathogenesis, particularly in men. Chronic pain can no longer be viewed solely as a symptom but as a process intertwined with cellular aging and longevity.

The therapeutic targeting of senescent cells represents an emerging avenue for intervention. While the translation of senolytic approaches into clinical practice requires caution and further validation, these findings open the possibility of addressing pain at its biological root rather than managing symptoms alone.

REFERENCES

1. Coryell, P.R., Diekman, B.O. & Loeser, R.F. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat Rev Rheumatol 17, 47–57 (2021). https://doi.org/10.1038/s41584-020-00533-7
2. Muralidharan, A., Sotocinal, S. G., Yousefpour, N., Akkurt, N., Lima, L. V., Tansley, S., Parisien, M., Wang, C., Austin, J. S., Ham, B., Dutra, G. M., Rousseau, P., Maldonado-Bouchard, S., Clark, T., Rosen, S. F., Majeed, M. R., Silva, O., Nejade, R., Li, X., Donayre Pimentel, S., … Mogil, J. S. (2022). Long-term male-specific chronic pain via telomere- and p53‑mediated spinal cord cellular senescence. The Journal of clinical investigation, 132(8), e151817. https://doi.org/10.1172/JCI151817
3. Sorge RE, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci. 2015.
4. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014.
5. Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to aging in vivo. Cell. 2017.